🔥🐔 BizChicken 🐔🔥

Companies Similar to Passage Bio, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. logo
Market Cap: Lowest
Employees: Lowest

Therapies for CNS diseases

Pasithea Therapeutics Corp. is a biotechnology company engaged in research and discovery of treatments for psychiatric and neurological disorders. It plans to operate anti-depression clinics and provide business support services, using trained pharmacists to administer intravenous infusions of ketamine. Founded in 2020, the company is based in Miami Beach, Florida.

Tags: CNS diseases, biotechnology, ketamine treatment, neurological disorders, psychiatric disorders

Symbol: KTTA

Recent Price: $2.95

Industry: Biotechnology

CEO: Dr. Tiago Reis Marques M.D., Ph.D.

Sector: Healthcare

Employees: 8

Address: 1111 Lincoln Road, Miami Beach, FL 33139

Phone: 702 514 4174

Last updated: 2024-12-31

Passage Bio, Inc.

Passage Bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

PBGM01, PBFT02, PBKR03, PBML04, PBAL05, PBCM06

Passage Bio, Inc. develops transformative therapies for central nervous system diseases using proprietary genetic medicine technologies to deliver functional genes for the treatment of various disorders.

Tags: AAVhu68, central nervous system, genetic medicines, proprietary technology, therapies

Symbol: PASG

Recent Price: $0.67

Industry: Biotechnology

CEO: Dr. William Chou M.D.

Sector: Healthcare

Employees: 58

Address: One Commerce Square, Philadelphia, PA 19103

Phone: 267 866 0311

Leadership

  • William Chou, MD, President and Chief Executive Officer
  • Kathleen Borthwick, Chief Financial Officer
  • Sue Browne, PhD, Chief Scientific Officer
  • Edgar B. (Chip) Cale, General Counsel and Corporate Secretary
  • Eden Fucci, SVP Technical Operations
  • Stuart Henderson, Chief Business Officer
  • Karl Whitney, PhD, SVP Global Regulatory Affairs
  • James M. Wilson, MD, PhD, Scientific Advisor
  • Maxine Gowen, PhD, Chairwoman
  • Athena Countouriotis, MD,
  • Derrell D. Porter, MD,
  • Dolan Sondhi, PhD,
  • Sandip Kapadia,
  • Tom Kassberg,
  • Saqib Islam,
  • Samiah Al-Zaidy, MD, Vice President, Clinical Development
  • Andrea Campanile, Vice President, Clinical Operations

Last updated: 2024-12-31

Pfizer Inc.

Pfizer Inc. logo
Market Cap: Highest
Employees: Highest

biopharmaceutical products

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide, offering medicines and vaccines across various therapeutic areas.

Tags: COVID-19, biopharmaceuticals, biosimilars, medicines, therapeutic areas, vaccines

Symbol: PFE

Recent Price: $26.42

Industry: Drug Manufacturers - General

CEO: Dr. Albert Bourla D.V.M., Ph.D.

Sector: Healthcare

Employees: 88000

Address: 235 East 42nd Street, New York, NY 10017

Phone: 212 733 2323

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for ß-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

Biomea Fusion, Inc.

Biomea Fusion, Inc. logo
Market Cap: Medium
Employees: Low

BMF-219

Biomea Fusion, Inc. is a biopharmaceutical company specializing in the discovery and development of covalent small molecule drugs for patients with genetically defined cancers and metabolic diseases. Their lead product candidate, BMF-219, targets multiple cancers.

Tags: BMF-219, biopharmaceutical, cancer, covalent drugs, metabolic diseases

Symbol: BMEA

Recent Price: $3.88

Industry: Biotechnology

CEO: Mr. Thomas Andrew Butler

Sector: Healthcare

Employees: 107

Address: 900 Middlefield Road, Redwood City, CA 94063

Phone: 650 980 9099

Last updated: 2024-12-31

Cogent Biosciences, Inc.

Cogent Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

CGT9486

Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.

Tags: biotechnology, genetically defined diseases, precision therapies, tyrosine kinase inhibitor

Symbol: COGT

Recent Price: $7.67

Industry: Biotechnology

CEO: Mr. Andrew R. Robbins M.B.A.

Sector: Healthcare

Employees: 164

Address: 200 Cambridge Park Drive, Cambridge, MA 02140

Phone: 617 945 5576

Last updated: 2024-12-31

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. logo
Market Cap: Low
Employees: Low

CB-010, CB-011, CB-012, CB-020

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.

Tags: CAR-NK, CAR-T, biopharmaceutical, cell therapies, clinical-stage, genome-edited therapies, hematologic malignancies, solid tumors

Symbol: CRBU

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Rachel E. Haurwitz Ph.D.

Sector: Healthcare

Employees: 158

Address: 2929 7th Street, Berkeley, CA 94710

Phone: 510 982 6030

Last updated: 2024-12-31

Fortress Biotech, Inc.

Fortress Biotech, Inc. logo
Market Cap: Lowest
Employees: Low

Pharmaceutical and Biotechnology Products

Fortress Biotech, Inc., is a biopharmaceutical company focused on developing and commercializing a range of dermatology products and late-stage product candidates for various medical conditions.

Tags: Menkes disease, NSCLC, acne treatment, amyloidosis, biopharmaceutical, biotechnology, cancer treatment, dermatology, immunodeficiency, pain management, pharmaceutical, vaccines

Symbol: FBIO

Recent Price: $2.18

Industry: Biotechnology

CEO: Dr. Lindsay Allan Rosenwald

Sector: Healthcare

Employees: 186

Address: 1111 Kane Concourse, Bay Harbor Islands, FL 33154

Phone: 781 652 4500

Leadership

  • Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer
  • Michael S. Weiss, Executive Vice Chairman, Strategic Development
  • David Jin, Chief Financial Officer and Head of Corporate Development
  • George Avgerinos, Ph.D., Senior Vice President, Biologics Operations
  • Samuel Berry, General Counsel and Corporate Secretary
  • Jimmie Harvey, Jr., M.D., Director
  • Malcolm Hoenlein, Director
  • Dov Klein, Director
  • J. Jay Lobell, Director
  • Kevin L. Lorenz, J.D., Director
  • Lucy Lu, M.D., Director

Last updated: 2024-12-31

Generation Bio Co.

Generation Bio Co. logo
Market Cap: Low
Employees: Low

genetic medicines

Generation Bio Co. is a genetic medicines company developing therapies for rare and prevalent diseases, with a focus on the liver, retina, skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and is headquartered in Cambridge, Massachusetts.

Tags: CNS, genetic medicines, liver, oncology, prevalent diseases, rare diseases, retina, skeletal muscle

Symbol: GBIO

Recent Price: $1.06

Industry: Biotechnology

CEO: Dr. Cameron Geoffrey McDonough M.D.

Sector: Healthcare

Employees: 174

Address: 301 Binney Street, Cambridge, MA 02142

Phone: 617 655 7500

Last updated: 2024-12-31

Gossamer Bio, Inc.

Gossamer Bio, Inc. logo
Market Cap: Low
Employees: Low

GB002, GB004, GB5121, GB7208

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics in immunology, inflammation, and oncology. Key products in development include GB002 for pulmonary arterial hypertension, GB004 for inflammatory bowel disease, GB5121 for primary central nervous system lymphoma, and GB7208 for multiple sclerosis.

Tags: biopharmaceutical, central nervous system lymphoma, immunology, inflammation, inflammatory bowel disease, multiple sclerosis, oncology, pulmonary arterial hypertension, therapeutics

Symbol: GOSS

Recent Price: $0.88

Industry: Biotechnology

CEO: Mr. Faheem Hasnain

Sector: Healthcare

Employees: 135

Address: 3013 Science Park Road, San Diego, CA 92121

Phone: 858 684 1300

Leadership

  • Faheem Hasnain, Chairman
  • Richard Aranda, M.D., Chief Medical Officer
  • Jeff Boerneke, General Counsel and Secretary
  • Matt Cravets, Senior Vice President, Biometrics
  • Bryan Giraudo, Chief Operating Officer & Chief Financial Officer
  • Lisa Nolan, Ph.D., Managing Director and President, Gossamer Bio Ireland
  • Caryn Peterson, Executive Vice President, Regulatory Affairs
  • Bob Smith, Chief Commercial Officer
  • Christian Waage, Executive Vice President, Technical Operations & Administration
  • Deanna Weber, Senior Vice President, Human Resources
  • Russell J. Cox, Director
  • Thomas Daniel, Director
  • Skye Drynan, Director
  • Sandra Milligan, Director
  • Steven D. Nathan, Director
  • John Quisel, Director

Last updated: 2024-12-31

Neurogene Inc.

Neurogene Inc. logo
Market Cap: Medium
Employees: Low

NGN-401, NGN-101

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases, focusing on gene therapy products like NGN-401 for Rett syndrome and NGN-101 for neuronal ceroid lipofuscinosis subtype 5 batten disease.

Tags: Rett syndrome, biotechnology, gene therapy, genetic medicines, life sciences, neurological diseases, neuronal ceroid lipofuscinosis

Symbol: NGNE

Recent Price: $22.28

Industry: Biotechnology

CEO: Dr. Rachel L. McMinn Ph.D.

Sector: Healthcare

Employees: 91

Address: 535 W 24th Street, New York, NY 10011

Phone: (877) 237-5020

Last updated: 2024-12-31

Palisade Bio, Inc.

Palisade Bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

LB1148

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing oral therapies targeting serious diseases related to the breakdown of the gastrointestinal mucosal barrier. Their lead product, LB1148, is designed to protect gut integrity during intestinal stress.

Tags: LB1148, biopharmaceutical, clinical-stage, gastrointestinal health, mucosal barrier, oral therapies

Symbol: PALI

Recent Price: $1.70

Industry: Biotechnology

CEO: Mr. J. D. Finley

Sector: Healthcare

Employees: 9

Address: 5800 Armada Drive, Carlsbad, CA 92008

Phone: 858 704 4900

Last updated: 2024-12-31

PDS Biotechnology Corporation

PDS Biotechnology Corporation logo
Market Cap: Low
Employees: Lowest

PDS0101

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101, is in Phase II clinical trial for treating various human papillomavirus-associated malignancies.

Tags: biopharmaceutical, cancer immunotherapies, clinical trials, clinical-stage, oncology, vaccines

Symbol: PDSB

Recent Price: $1.69

Industry: Biotechnology

CEO: Dr. Frank K. Bedu-Addo Ph.D.

Sector: Healthcare

Employees: 25

Address: 25B Vreeland Road, Florham Park, NJ 07932

Phone: 800 208 3343

Leadership

  • Frank Bedu-Addo, Ph.D., Chief Executive Officer, Director
  • Stephan Toutain, Chief Operating Officer
  • Lars Boesgaard, Chief Financial Officer
  • Gregory Conn, Ph.D., Chief Scientific Officer
  • Kirk Shepard, M.D., Chief Medical Officer
  • Spencer Brown, Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
  • Rory Cullinane, Vice President of Quality
  • Joe Dervan, Ph.D., Vice President of Research and Development
  • David Schaaf, M.D., Vice President of Medical Affairs
  • Sir Richard Sykes, Director
  • Ilian Iliev, Ph.D., Director
  • Gregory Freitag, J.D., CPA, Director
  • Otis W. Brawley, M.D., Director
  • Kamil Ali-Jackson, J.D., Director
  • Stephen Glover, Chairman

Last updated: 2024-12-31

PepGen Inc.

PepGen Inc. logo
Market Cap: Low
Employees: Low

PGN-EDO51

Pep Gen Inc. is a clinical-stage biotechnology company developing oligonucleotide therapeutics for neuromuscular and neurologic diseases. Its lead product, PGN-EDO51, is in Phase I trials for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, biotechnology, clinical trials, neuromuscular diseases, oligonucleotide therapeutics

Symbol: PEPG

Recent Price: $3.83

Industry: Biotechnology

CEO: Dr. James G. McArthur Ph.D.

Sector: Healthcare

Employees: 72

Address: 245 Main Street, Cambridge, MA 02142

Phone: 781-797-0979

Last updated: 2024-12-31

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. logo
Market Cap: Medium
Employees: Medium

platform for cell programming

Ginkgo Bioworks Holdings, Inc. develops a platform used to program cells for biological production of products such as therapeutics, food ingredients, and chemicals. It serves markets in specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Tags: agriculture, biotechnology, cell programming, food ingredients, novel therapeutics, pharmaceuticals, specialty chemicals

Symbol: DNA

Recent Price: $9.44

Industry: Biotechnology

CEO: Dr. Jason Kelly

Sector: Healthcare

Employees: 1218

Address: 27 Drydock Avenue, Boston, MA 02210

Phone: 877 422 5362

Last updated: 2024-12-31

BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. logo
Market Cap: High
Employees: Medium

AG10, BBP-265, BBP-831, BBP-631, Encaleret

Bridge Bio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases, with a pipeline of 30 programs including candidates like AG10, BBP-265, and others in various stages of clinical trials.

Tags: biopharmaceuticals, clinical trials, drug development, genetic diseases

Symbol: BBIO

Recent Price: $27.32

Industry: Biotechnology

CEO: Dr. Neil Kumar Ph.D.

Sector: Healthcare

Employees: 550

Address: 421 Kipling Street, Palo Alto, CA 94301

Phone: 650 391 9740

Last updated: 2024-12-31

PaxMedica, Inc. Common Stock

PaxMedica, Inc. Common Stock logo
Market Cap: Lowest
Employees: Lowest

PAX-101

Pax Medica, Inc., is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for treating intractable neurologic disorders. Their lead product, PAX-101, is an intravenous formulation of suramin for indications such as autism spectrum disorder and chronic fatigue syndrome.

Tags: Autism Treatment, Biopharmaceutical, Chronic Fatigue Syndrome, Drug Development, Neurologic Disorders

Symbol: PXMD

Recent Price: $0.06

Industry: Biotechnology

CEO: Mr. Howard J. Weisman

Sector: Healthcare

Employees: 6

Address: 303 South Broadway, Tarrytown, NY 10591

Phone: 914-987-2876

Last updated: 2024-12-31